Boehringer Ingelheim has not announced any major settlements ... allowed plaintiffs to present crucial expert testimony that ...

Boehringer Ingelheim, a former manufacturer that has not settled, is in court in California this week defending itself in a jury trial brought by a man who claims that over-the-counter Zantac ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK’s move doesn’t end litigation around Zantac as other drugmakers are still facing trials, including Boehringer Ingelheim GmbH, which is facing a jury trial in Oakland.

Boehringer Ingelheim is the exception. It has not announced any major settlements. A drug under the name of Zantac 360, which contains no ranidine, is still being currently sold.

Boehringer Ingelheim has not announced any major settlements ... allowed plaintiffs to present crucial expert testimony that Zantac caused cancer. The drug companies had sought to keep that ...

Pfizer has agreed to settle most of the Zantac cases against it in state court, according to its most recent financial statement, and Sanofi in April announced that it was settling about 4,000 cases.